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Image registration accuracy was<2mm for all anatomic head and neck 
landmark displacements in the x, y and z direction relative to CT.  
Image quality was found to be comparable to the commissioning 
benchmark. SNR data for T1 FSE and T2 FSE were not statically 
significantly different (p= 0.53, 0.10) from benchmark dataset. 
However, the benchmark configuration appears to provide more 
optimized signal across all anatomical structures. For superficial 
structures closer to the surface, e.g. parotid, the RT coil provides 
very high signal due to closer proximity of the coil (T1 FSE mean RT 
126.1 v diagnostic 99.8). For deeper structures the converse is true, 
e.g. brainstem (mean SNR RT 33.7 v diagnostic 58.2).  
Conclusions: Benchmarking of the system and clinical process has 
allowed for the development of an MR-SIM quality assurance program 
for this anatomical site, with well defined imaging and image 
registration metrics.  
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Purpose/Objective: The dose-volume effect of radiation on breast 
tissue is poorly understood with few attempts at modeling the Normal 
Tissue Complication Probability (NTCP). This study estimates the NTCP 
parameter values for breast fibrosis after external beam breast 
radiation therapy (RT).  
Materials and Methods: Individual patient data of 5282 patients from 
the multi-centre EORTC 22881-10882 'boost versus no boost' trial and 
574 patients from the Cambridge breast IMRT trial were pooled and 
analysed. All patients received whole breast irradiation (WBI) (40Gy in 
15 fractions over 3 weeks or 50Gy in 25 fractions over 5 weeks) 
followed by tumour bed (TB) boost in some cases. A two compartment 
dose volume histogram (DVH) model was used with TB volume 
receiving WBI plus boost dose as the first compartment and whole 
breast volume outside the TB volume receiving WBI dose alone as 
second compartment. Two NTCP models were considered: (a) Lyman 
Kutcher Burman (LKB) model and (b) Niemierko model. The model 
parameters (BEUD50, m or γ50 and n)) for moderate-severe breast 
fibrosis were estimated using the Maximum Likelihood Estimation 
(MLE) method. To account for hypofractionation, a biologically 
equivalent dose (BED3) was generated using α/β of 3Gy. The 
parameter 95% confidence intervals (CI) were generated using the 
Profile Likelihood Estimation method. Summary data from the START 
pilot trial (n=1410) were used to asses the goodness of fit of the 
predicted NTCP model using the Pearson chi-square test. 
Results: One hundred and fifty four patients (26.8%) in the Cambridge 
trial and one thousand and ninety six patients (20.7%) in the EORTC 
trial developed moderate-severe breast fibrosis. Using the MLE 
method, the best estimated NTCP parameters were BEUD3(50) 
=136.4Gy, γ50=0.9 and n=0.011 for the Niemierko model and 
BEUD3(50) =132Gy, m=0.35 and n=0.012 for the LKB model. A small 
value of volume parameter 'n' suggests that for moderate-severe 
fibrosis, breast tissue is a serial organ. The observed rates of 
moderate-severe fibrosis in the START pilot trial were in good 
agreement to the predicted rates from the above models (χ2=0.05; 
p=0.95 with five degrees of freedom) Figure 1. 
 
 
Conclusions: This large multi-centre pooled study indicates that the 
effect of volume parameter is small and the maximum radiotherapy 
dose is the most important parameter to influence late breast fibrosis. 
Clinical validation of these results from future prospective studies is 
suggested. 
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Purpose/Objective: Breast cancer is the most commonly diagnosed 
female cancer, and with good survival rates, it is imperative that any 
potential long term side effects from this effective treatment are 
reduced. Techniques specific to patient cohorts with differing local 
recurrence risk factors are likely to be the new standard of care in 
breast radiotherapy in 5 to 10 years. These techniques include 
simultaneous integrated boost (SIB) and conformal non co-planar 
beam arrangements for accelerated partial breast irradiation (APBI). 
These beam arrangements distribute the dose throughout the body in 
a different pattern to the standard treatment. This work reports a 
comparison of the risk for these modern radiotherapy techniques, 
including the use of image guidance.  
Materials and Methods: Five treatment plans were created on a 
patient CT scan: standard whole breast treatment (WBRT), conformal 
non co-planar five field plan for an APBI treatment, two volume/two 
dose level SIB plan with 5 fields, three volume/three dose level SIB 
plan with 7 fields (forward planned), three volume/three dose level 
SIB plan with 7 fields (inverse planned). The plans were transferred to 
a whole body phantom. Regions in the phantom which represented 
radiosensitive organs were delineated and thermoluminescent 
dosimeters (TLD) used to measure the dose. Dose from a breast 
imaging kilovoltage cone beam CT protocol was measured with TLD in 
the same regions. These dose data were used as input into the 
Biological Effects of Ionising Radiation Report VII models of second 
cancer induction and lifetime risks calculated for the five treatment 
classes and intensive imaging regimes. 
Results: The lifetime risk data showed that complex radiotherapy 
techniques did not increase the theoretical risk of second cancer 
incidence for organs distant from the treated breast, or the 
contralateral breast where appropriate constraints were applied. SIB 
treatments were predicted to increase the lifetime risk of second 
cancer incidence in the lungs compared to standard breast 
radiotherapy; this was outweighed by the threefold reduction in 5 yr 
local recurrence risk with adjuvant radiotherapy for a high risk cohort 
for whom these treatments are appropriate. A lower lifetime risk of 
second cancer in the contralateral breast was predicted for the APBI 
method, compared with WBRT. The contribution of imaging dose to 
the total dose from both treatment and imaging did not exceed 22% 
for any measured organ. 
Conclusions: Modern complex radiotherapy techniques used in breast 
cancer were not predicted to increase the theoretical risk of second 
cancer incidence in organs far from the treated breast. Where 
increases in the lifetime risk of induced second cancer were 
predicted, these remained small compared to the large reduction in 
local recurrence risk from receiving RT as a component of treatment. 
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The use of image guidance is unlikely to result in an unacceptable 
increase in second cancer risk. 
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Purpose/Objective: Understanding the dose-response of the normal 
lung in order to minimize the risk of radiation pneumonitis (RP) is of 
critical importance for optimization of radiotherapy for lung cancer. 
In this study, we propose a method to combine the dose-response 
relationship for RP from the landmark QUANTEC paper with clinical 
risk factors in order to improve individual patient risk prediction. The 
approach is validated in an independent dataset of 103 patients. 
Materials and Methods: The prevalence of risk factors (pulmonary co-
morbidities, smoking history, age and chemotherapy) in the patient 
populations underlying the QUANTEC analysis was estimated, and a 
previously published method to adjust the dose-response relationship 
for clinical risk factors was employed. Estimates of effect size (odds 
ratios, OR) for clinical risk factors were drawn from a recently 
published meta-analysis. Baseline values for D50 (the dose resulting in 
a 50 % complication probability) and γ50 (the normalised slope of the 
dose-response curve at D50) were established. Confidence intervals 
were estimated using random sampling. The method was tested in an 
independent dataset (103 non-small cell lung cancer patients), 
comparing the predictive power of the dose-only QUANTEC model and 
the model taking risk factors into account. Subdistribution cumulative 
incidence functions for RP were compared in stratified analyses for 
patients with high / low risk predictions, based on group medians, 
from the two models, and concordance indices (c-indices) for the 
prediction of RP were calculated. C-indices were compared using a 
Student t-test for paired samples. 
Results: The logistic relationship between mean lung dose and the risk 
of RP was described in the QUANTEC paper by D50 = 30.8 Gy, γ50 = 
0.97. From this, a reference dose-response relationship for a patient 
without pulmonary co-morbidities, no history of smoking, below 63 
years old, and not treated with sequential chemotherapy was 
estimated as D050 = 32.3 Gy (95% CI: 28.9, 36.5), γ050 = 1.10 (95% CI: 
0.92, 1.31). ORs for each risk factor were then used to calculate 
individual patient risk estimates. The cumulative incidences of RP in 
the validation dataset were not significantly different in high / low 
risk patients stratified according to the QUANTEC model (p=0.11), but 
were significantly different using the individualized model (p=0.006, 
see Figure 1). The c-indices were significantly different between the 
dose-only and the individualized model (p=0.004 using binary risk 
allocation, p=0.04 using continuous NTCP as predictor). 
Conclusions: This study presents a method to combine a dose-
response function with known clinical risk factors, based on data from 
large, published meta-analyses. We demonstrate that the predictive 
power of the combined model is greater than a dose-only model in an 
independent dataset. This method, although not taking correlations 
between risk factors into account, allows for individualization of dose 
constraints and risk estimations, and it can easily be extended to 
include additional risk factors. 
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Purpose/Objective: (1) To prospectively determine the prevalence of 
patient-reported xerostomia after sparing the contralateral 
submandibular gland (cSMG) in oropharyngeal cancer patients without 
contralateral lymph node metastases. (2) To construct a normal tissue 
complication probability (NTCP) curve for submandibular gland(SMG) 
function after radiotherapy (RT) based on mean dose and selective 
flow measurements. 
Materials and Methods: 50 oropharyngeal cancer patients (cT1-4N0-
2bM0) were treated with an optimized IMRT-technique with the 
intention to spare both parotid glands (PGs) and the cSMG (aim cSMG 
<40 Gy; cSMG-sparing cohort). They were compared with a historical 
cohort of 52patients that received only PG-sparing IMRT (PG-sparing 
cohort). cSMG- and PGflow rates were measured 6 weeks and 1 year 
post-RT and converted into the percentage of baseline. Patient-
reported xerostomia was recorded using the EORTC QLQ-H&N35 single 
items xerostomia and sticky saliva. For NTCP-analysis, SMG flow data 
from a large patient cohort were fitted to the Lyman-Kutcher-Burman 
model with a complication defined as SMG flow ratio <25% of pre-RT 
flowrate (RTOG/EORTC grade 4 xerostomia). 
Results: cSMG mean dose could be reduced below 40 Gy in 50% and 
21% of the patients in the cSMG-sparing and PG-sparing cohorts (mean 
cSMG dose 39.1 vs 50.4 Gy) respectively. cSMG flow ratio, 
complication rate and xerostomia scores 1 year post-RT were slightly 
better in the cSMG-sparing cohort (ns). At 1 year, 56% of the patients 
from the cSMG-sparing cohort still reported grade 2-3 xerostomia.  
Post-hoc, patients were re-grouped according to mean cSMG dose 
above (n= 66) or below (n= 36) 40 Gy. All patients but one in the <40 
Gy group had a small (T1-T2) tumor and 53% received only unilateral 
neck-RT. Significantly higher cSMG flow ratios at 6 weeks and 1 year 
post-RT in the <40 Gy group translated into lower xerostomia scores at 
both time points (at 1 yr: 67 vs. 42% grade 2-3 xerostomia, p= 0.07). 
PG function (1 yr) was similar in both groups. LKB-modelling showed 
substantial shift of NTCP-curve between 6 weeks and 1 year post-RT: 
the TD50 (mean dose leading to 50% NTCP) was 23 and 35 Gy,resp. 
Above 40 Gy mean SMG dose, NTCP worsened between 6 weeks and 1 
year post-RT.  
See figure for the 1 year NTCP-curve. 
  
Conclusions: This study concerns the largest group of patients pub-
lished, for which a dose response curve for SMG-flow rate after radio-
therapy was analysed. cSMG mean doses below 40 Gy resulted in 
improved SMG function and reduced patient-reported xerostomia. 
Above 40 Gy submandibular function worsened in time. cSMG-sparing 
in oropharyngeal cancer patients(N-stages ≤N2b) is still challenging.  
 
 
 
